Efficacy and safety of amisulpride for schizophrenia

Abstract

Abstract:

AIM: To explore the efficacy and safety of amisulpride in treating patients with schizophrenia. METHODS: Ninety patients with schizophrenia were randomly divided into the experimental group (received amisulpride) and the control group (received risperidone) with forty-five cases in each group. The Positive and Negative Syndrome Scale (PANSS) was used to assess the patients' mental symptoms and the Clinical Global Impressions-Severity of Illness Scale (CGI-S) for the degree of severity; the efficacy was assessed through the changes of scores, the improvement rate and effective rate of symptoms. The Treatment Emergent Symptom Scale (TESS) was assessed to evaluate the adverse reactions. All scales were assessed before treatment and at the 2nd, 4th, 8th weekend after treatment. RESULTS:The scores of PANSS and all its factor scores at every time interval were significantly lower than those at baseline (P<0.05). The scores of negative symptoms in the experimental group were much lower than those in the control group at the 2nd, 4th, 8th weekend after treatment (P<0.05). There's no difference in total scores of PANSS, scores of positive symptoms and psychopathological symptoms between the two groups at every time interval (P>0.05). Scores of CGI-S in the experimental group was obviously lower than those at baseline in comparison with the control group (P<0.01). There's no difference in scores of CGI-S between the two groups (P>0.05). Both of two groups presents no severe adverse reactions after treatment, and no significant difference was observed between the two groups either (P>0.05). CONCLUSION: Both amisulpride and risperidone can obviously improve patiens' positive, negative and psychopathological symptoms. However, the efficacy on negative symptoms of amisulpride is better than that of risperidone. Amisulpride also exhibit better tolerance with no severe adverse reaction in treating schizophrenia.

Key words: schizophrenia, amisulpride, risperidone

CLC Number:

R749

ZHOU Yong, Chen Xuefang, HUANG Hanjin. Efficacy and safety of amisulpride for schizophrenia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(10): 1152-1157.

References

［1］江开达.精神病学高级教程［M］//赵靖平,精神分裂症.北京：人民军医出版社，2009：125-143.
［2］Tandon R, Keshavan MS, Nasralllah HA. Schizophrenia. "Just the facts" What we know in 2008. 2. Epidemiology and etiology［J］. Schizophr Res, 2008,102(1/2/3):1-18.
［3］Moller HJ, van Praag HM, Aufdembrinke B,et al. Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia［J］. Psychopharmacology (Berl), 1994, 115(1/2):221-228.
［4］Perrault G, Depoortere R, Morel E, et al. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity［J］. J Pharmacol Exp Ther, 1997, 280(1):73-82.
［5］Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia［J］. Drugs, 2001,61(14):2123-2150.
［6］Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride,an unusual'atypical' antipsychotic: a meta-analysis of randomized controlled trials［J］. Am J Psychiatry, 2002, 159(2):180-190.
［7］江开达，精神病学高级教程［M］//司天梅, 精神药物治疗.北京：人民军医出版社，2009：280-296.
［8］Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010:a systematic analysis for the Global Burden of Disease Study 2010［J］. Lancet，2012,380（9859）: 2163-2196.
［9］Martin S, Ljo H, Peuskens J, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months［J］. Curr Med Res Opin， 2002,18（6）:355-362.
［10］Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicenter,double-blind study (the Amisulpride Study Group)［J］. Eur Psychiatry，2000,15（5）:321-329.
［11］Peuskens J, Bech P, Moller HJ, et al. Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group［J］. Psychiatry Res，1999,88（2）:107-117.
［12］Rzewuska M, Kuczyński W, Luks M. Effectiveness and tolerability of amisulpride in patients with schizophrenia: results of a 6-month open study［J］. Psychiatr Pol，2004，38(3):453-468.
［13］Loo H, Poirier-Littre MF, Theron M, et al. Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia［J］. Br J Psychiatry,1997,170:18-22.
［14］Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride［J］. Am J Psychiatry, 1999,156(4):610-616.
［15］Boyer P, Lecrubier Y, Puech AJ, et al. Treatment of negative symptoms in schizophrenia with amisulpride［J］. Br J Psychiatry, 1995,166(1):68-72.
［16］Leucht S, Pitschel-Walz G, Engel R, et al. Amisulpride-an unusual atypical antipsychotic. Ameta-analysis of randomized controlled trials［J］. Am J Psychiatry, 2002,159(2):180-190.
［17］Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia［J］. Drugs, 2001, 61(14):2123-2150.

[1]	LI Na, HAN Hongcan, WANG Jun. General considerations for bioequivalence studies with pharmacokinetic methods for anti-schizophrenic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1419-1425.
[2]	YAN Pan, SHI Jianfei, LI Jing, WANG Shengdong, WANG Shuqi, WANG Chengpeng, SONG Mingfen. Effects of DRD2 and 5-HTR2A gene polymorphisms and their interaction on olanzapine in the treatment of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1131-1138.
[3]	ZHANG Jiaxuan, DENG Shunshun, QIU Mali, YANG Shuangshuang. Changes in serum thyroid hormone levels in psychiatric patients after risperidone monotherapy or polytherapy treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1145-1150.
[4]	WAN Ping, LIU Liang, ZHANG Ping, ZHANG Zhongdong. Influential factors of serum concentration/dosage ratio for schizophrenia patients after oral administration of olanzapine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1024-1029.
[5]	FAN Yao, XUE Yong, WANG Xin, CHEN Xuefei, ZHANG Xu, YAO Yingshui, SHEN Chong. Association analysis of apolipoprotein E polymorphisms and weight loss among schizophrenia patients with risperidone treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 288-295.
[6]	CAI Dandan, GUI Donghui, ZHANG Jianbing, ZHOU Wenhua. Clinical efficacy of low dose risperidone combined with trazodone in the treatment of heroin addicts during detoxification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(1): 94-98.
[7]	CAO Ting, LI Nana, CAI Hualin. Progress in neurosteroids related to the pathogenesis and treatment of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 709-714.
[8]	CUI Lijun, PAN Xin, ZHU Jielin, LI Jianhua. Effect of paliperidone and olanzapine on patients with first-episode schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 466-470.
[9]	HANG Rong-hua, LI Ye-ping, WU Ming-fei, LI Rui. Relationship on medication compliance, antipsychotic side-effects and social support in schizophrenia outpatients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(8): 912-915.
[10]	NI Ping, LV Hai-long, GUO Xiao-feng, ZHANG Li-li, XU Lin-yong. Comparison of curative effect and clinical influence factors of risperidone and olanzapine in the treatment of acute phrase of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 182-185.
[11]	ZHONG Zhi-yong, ZHANG Ming, WANG Ji-hui, WU Xiao-li. A retrospective study of risperidone oral solution versus olanzapine tablets in treating brain organic mental disorders [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1047-1051.
[12]	TANG Ya-mei, ZHANG Xiang-hui, LIU Yong. Concentration change of NE, 5-HT and their metabolites in brain tissue in schizophrenia developmental models rat repeatedly treated with MK-801 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 721-726.
[13]	HANG Rong-hua, CHENG Wan-liang, WANG Rui-quan, WU Ming-fei. Efficacy and executive function of olanzapine and risperidone in the treatment of elderly patients with schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 812-815.
[14]	LIU Lin-jing, XIU Mei-hong, ZHANG Xiang-yang, CHEN Da-chun. Effect of risperidone on S100B levels and relationship with treatment response in first-episode schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 313-317.
[15]	XU Ben-jian, CHEN Ju-feng. Efficacy and safety of paliperidone extended-release tablets as substituting medication in acute patients with schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 215-219.